Mirum Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation Gilti Percent
Mirum Pharmaceuticals, Inc. (MIRM) reported Effective Income Tax Rate Reconciliation Gilti Percent of 1.69% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement
us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent · last filed 2024-03-15
- Mirum Pharmaceuticals, Inc. effective income tax rate reconciliation gilti percent for fiscal 2023 was 1.69%, a 18.18% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. effective income tax rate reconciliation gilti percent for fiscal 2022 was 1.43%.
- Mirum Pharmaceuticals, Inc. effective income tax rate reconciliation gilti percent for fiscal 2021 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation Gilti Percent 12 month |
|---|---|
| 2023-12-31 | 1.69% 10-K · filed 2024-03-15 |
| 2022-12-31 | 1.43% 10-K · filed 2024-03-15 |
| 2021-12-31 | 0.00% 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |